June 26, 2023: In our public comment, NCHR supports the FDA’s survey on evaluating patients’ understanding of quantitative information provided in prescription drug advertising. We strongly recommend adding an assessment of comprehension for factors such as relative risk, absolute risk, relative benefit, and absolute benefit of drugs. We urge the FDA to include a diverse demographic of participants in the one-on-one interview informing the survey and provide details about the number of interviews OPDP plans to conduct.
Read More »On Health Policy
NCHR Comments on USPSTF Draft Recommendation for Oral Health in Adults
June 20, 2023: In our public comment, NCHR agrees with USPSTF that there is insufficient evidence to recommend routine oral health screening of adults by primary care clinicians. We urged that new research be conducted to determine the benefits and harms of screening, primary care counseling, dental referral, and oral health preventive interventions administered in primary care settings for adults.
Read More »NCHR Comments on USPSTF Draft Recommendation for Oral Health in Children and Adolescents
June 20, 2023: In our public comment, NCHR agrees with USPSTF that there is insufficient evidence to recommend routine oral health screening by primary care clinicians in children ages 5 to 17 years. Available research evidence is limited to studies assessing oral health preventive interventions that were administered by dental professionals or in supervised school settings, but not in primary care settings. We strongly recommend that well-designed research be conducted to fill these gaps.
Read More »NCHR Testimony at the FDA Oncologic Drugs Advisory Committee Meeting on Pediatric Dosage for Cancer Drugs, June 16, 2023
June 16, 2023: NCHR testified on how to choose dosages for pediatric cancer drugs, stating that variables such as weight, age, sex, race, and organ impairment should be studied to identify differences in safety or effectiveness for subpopulations. We also strongly support the specifications about drug safety and tolerability, requiring factors such as duration of exposure and adverse events to be compared across varying dosages.
Read More »NCHR Comments on EPA Greenhouse Gas Emission Standards for Heavy-Duty Vehicles
June 16, 2023: NCHR responds to EPA’s request for public comments on the new emission standards for heavy-duty vehicles. We strongly urge the EPA to strengthen the proposed standards by requiring 100% zero-emission sales by 2035 in the final rule to protect public health and set the United States on a path to a zero-emissions future.
Read More »